Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.

Get key insights into Talkspace's Q2 2025 earnings, with 18% revenue growth, AI innovation, payer momentum, and expanding partnerships driving ...

Tariffs— Shawn Munsell stated, "Under the 10% tariff environment, our exposure without mitigation could approach $8 million ...